Medicus Pharma says U.S. FDA has provided comments on Phase 2 Clinical Protocol of SKNJCT-003
Published on March 28, 2024 –News Direct–
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to share significant updates regarding the company’s interaction with the U.S Food and Drug Administration (FDA). Medicus Pharma has received comments from the FDA, pertaining to its recent study findings and regulatory submissions.
The FDA’s feedback regarding the study results is considered exploratory, with specific requests directed towards providing additional data from clinical studies to support the doses of 100μg and 200μg of micro-array needles containing doxorubicin. Additionally, the FDA has requested an updated investigator brochure, incorporating insights from the clinical studies SKNJCT-001 and SKNJCT-002, focusing particularly on adverse events and dose-limiting toxicities at each dose level.
Dr. Bokhari conveyed to Proactive that the SKNJCT-001 study successfully met its primary objective of assessing safety and tolerability. The investigational product, D-MNA, demonstrated favorable safety profiles across all dose levels among the thirteen participants enrolled in the study. This encouraging outcome underscores the potential of D-MNA as a safe and well-tolerated therapeutic option.
In response to the FDA’s requests, Medicus Pharma is committed to making a comprehensive submission in the second quarter of 2024. This submission will include the requested data and an updated investigator brochure, meticulously incorporating insights from the SKNJCT-001 and SKNJCT-002 studies. Furthermore, the submission will encompass Chemistry, Manufacturing, and Controls (CMC) stability data, ensuring a comprehensive and robust dossier.
Dr. Bokhari reiterated Medicus Pharma’s dedication to adhering to regulatory guidelines and fostering transparent communication with regulatory authorities. By addressing the FDA’s queries and providing comprehensive data, the company aims to facilitate the regulatory review process and advance the development of D-MNA towards potential regulatory approval.
In summary, Medicus Pharma remains steadfast in its commitment to advancing innovative therapies while upholding the highest standards of safety and efficacy. The company’s proactive engagement with regulatory agencies reflects its dedication to bringing impactful treatments to patients in need.
Contact Details Proactive North America
Proactive North America
+1 604-688-8158
[email protected]
View source version on newsdirect.com: https://newsdirect.com/news/medicus-pharma-says-u-s-fda-has-provided-comments-on-phase-2-clinical-protocol-of-sknjct-003-575151078
News Direct is a content & news distribution platform purpose-built for the demands of strategic communications today. News Direct provides powerful performance advantages to help PR, Corp Comms and IR professionals excel in their media outreach efforts.
View This Press Release On
medicus-pharma-says-u-s-fda-has-provided-comments-on-phase-2-clinical-protocol-of-sknjct-003
Recent Press Releases
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Press Release
Mission Statement
At Hexa PR Wire, our mission is to help businesses of all sizes achieve their marketing goals through high-quality press release distribution services. We believe that every business has a unique story to tell, and we are committed to helping our clients share their message with the world.
We are dedicated to providing exceptional customer service and ensuring that our clients’ press releases are distributed to the right people, at the right time, and in the right way.
Contact
Get immediate support by scanning the QR code below
Sitemap
Resources
Press Release Preparation: What We Need from You
The Power of Press Releases: Why Your Personal Brand or Company Needs Them
Submitting a Press Release with Hexa PR Wire
Guidelines For Publishing Your Press Release on Hexa PR Wire
What are Press Releases Intended For
© 2022 Hexa Web Systems, inc.
